The BCL11B Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 786-O human renal cell adenocarcinoma cell line. This product features targeted disruption of the BCL11B gene, a critical zinc finger transcription factor, generating a heterogeneous loss-of-function model suitable for diverse functional studies. The polyclonal format retains the complexity of edited alleles without clonal selection, providing a robust platform for investigating BCL11B-dependent processes.
The 786-O host cell line is a well-established model of clear cell renal cell carcinoma (ccRCC), harboring a characteristic VHL mutation that mimics the genetic background of the majority of sporadic ccRCC cases. These epithelial cells maintain key features of renal carcinoma, including dysregulated hypoxia signaling and altered metabolic pathways, making them a valuable system for dissecting molecular mechanisms underlying kidney cancer. The VHL-mutant context provides a relevant tumor microenvironment for examining the interplay between BCL11B and pathways such as hypoxia-inducible factor signaling.
BCL11B functions as a zinc finger transcription factor that directly regulates gene expression by binding to DNA response elements and recruiting chromatin-modifying complexes. In T-cell biology, it acts downstream of NOTCH1 and GATA3, integrating signals from the T-cell receptor and the Notch pathway to orchestrate lineage commitment. BCL11B interacts with factors including SIRT1, HDAC1, CTBP1, and RUNX1, modulating transcriptional repression or activation. Known downstream targets encompass CDKN1A, BAX, and CCND1, linking BCL11B to cell cycle control and apoptosis. Additionally, BCL11B engages Wnt/??-catenin signaling through upstream TCF7 and downstream HES1.
In the context of renal cell carcinoma, BCL11B exhibits context-dependent activities, potentially acting as either a tumor suppressor or an oncogene. The 786-O polyclonal knockout cells enable dissection of these dual roles, particularly in relation to VHL loss and ccRCC progression. By disrupting BCL11B in this defined genetic background, researchers can evaluate its contribution to proliferation, survival, and metastatic potential. This model is instrumental for understanding how BCL11B modulates gene expression programs in renal epithelial cells and for identifying synthetic lethal interactions or therapeutic vulnerabilities.
Typical research applications of this polyclonal knockout cell population span T-cell development studies, cancer biology, transcriptional regulation, and apoptosis mechanisms. Investigators can employ a range of representative assays including Western blotting and RT-qPCR for expression analysis, ChIP-qPCR for probing DNA-binding dynamics, flow cytometry for phenotypic profiling, and functional assays such as apoptosis, migration, and invasion studies. The heterogeneous editing pattern reflects the complexity of gene disruption in a tumor cell population, making it suitable for pooled screening approaches and for assessing overall gene function without clonal bias. For additional information and technical support, please contact Ascent Research.
